Diagnostics
PSMA-B Ligand
PSMA-B Ligand
A significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment, particularly in the development of highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and targeted therapy delivery using radio labelled PSMA ligands.
Theranostic molecules are suitable for diagnosis and therapy of cancers.
A Breakthrough in Therapy
In a discovery project to develop a novel, boron-containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we discovered PSMA-B, a molecule containing boron and demonstrating nanomolar binding activity to PSMA.
Preclinical evaluations have been initiated to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic reagent and as a targeted prostate cancer therapeutic.
Advancing Prostate Care
We have entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of ligand to the prostate-specific membrane antigen as a potential theranostic molecule.